When a patient arrives in the cardiac catheterization lab suffering a ST-elevation myocardial infarction (STEMI) — a complete blockage of a coronary artery — the priority is clear: open that artery, fast. But a growing body of evidence is raising a harder question: what should be done about the other diseased vessels found during that same procedure?

For patients with multivessel coronary artery disease (CAD), affecting roughly 10–35% of all STEMI cases, the decision of whether to treat non-culprit lesions immediately, in a staged procedure, or not at all has become one of interventional cardiology's most contested debates. The latest data suggests the aggressive "fix it all now" approach may do more harm than good.

Key Finding

A 2026 meta-analysis of 9 randomized trials and 4,213 patients found that immediate complete revascularization was associated with more than twice the risk of cardiac mortality at 30 days compared with a staged strategy, with a risk ratio of 2.19 (95% CI 1.08–4.44).6

Why Multivessel Disease Complicates STEMI Care

STEMI occurs when one specific coronary artery — the culprit vessel — becomes abruptly occluded. Primary percutaneous coronary intervention (PCI) to restore flow in that artery is the gold standard of care. The challenge arises when imaging reveals that other coronary arteries also carry significant atherosclerotic plaques.

The rationale for immediate complete revascularization seems intuitive: the patient is already on the table, already anticoagulated, and already prepped. Why not treat all disease at once and avoid another procedure? For years, many interventionalists operated on exactly this logic — and current guidelines from both the ACC/AHA and the European Society of Cardiology (ESC) have endorsed complete revascularization with a Class I recommendation. However, the weight of emerging evidence is now challenging whether the timing of that strategy matters as much as the strategy itself.

4,213
patients across 9 randomized trials in latest meta-analysis
2.19×
higher cardiac mortality risk at 30 days with immediate vs. staged PCI
2.0%
all-cause mortality at 30 days with immediate PCI vs. 1.2% staged
30 days
critical short-term window where risk differential is highest

The Case Against Doing Everything at Once

During a STEMI, the body is in a profoundly abnormal state. Catecholamine surges, microvascular dysfunction, heightened clotting activity, and systemic inflammation all conspire to make the coronary vasculature unpredictable. Intervening on a non-culprit vessel in this context carries specific risks that simply do not apply during a calm, elective procedure days or weeks later.

Contrast load is a major concern. Extended procedures require substantially more contrast agent, elevating the risk of contrast-induced nephropathy. Procedure time itself compounds radiation exposure and vascular access complications. Perhaps most importantly, non-culprit plaques that appear angiographically significant may be functionally less severe than they look — a judgment that is best made with fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) under stable conditions, not in the midst of an acute infarct.

A particularly important methodological concern is the difficulty of detecting procedural myocardial infarction during immediate complete revascularization. Because cardiac biomarkers are already elevated and have not yet peaked, and ST-segments are already abnormal at the time of the index STEMI, any ischemic injury caused by intervening on a non-infarct-related artery during the same session would be nearly impossible to identify objectively. This means that trials comparing immediate versus staged strategies may systematically underestimate procedural MI risk in the immediate group — potentially biasing results in favor of that approach.6

What the Data Show

Several landmark trials — including PRAMI, CvLPRIT, COMPLETE, MULTISTARS AMI, BIOVASC, OPTION-STEMI, and iMODERN — have explored this question with nuanced and at times contradictory results. Some showed that immediate multivessel PCI was noninferior to a staged approach; others found it was not noninferior. The COMPLETE trial demonstrated benefit for complete revascularization, but critically this was achieved through a staged procedure after stabilization — not during the index event.

The 2026 meta-analysis by Elbahloul et al., pooling data from nine randomized trials and over 4,200 patients, brings greater clarity.6 While all-cause mortality at 30 days trended higher with immediate PCI (2.0% vs. 1.2%; RR 1.66), the difference in cardiac mortality at 30 days was statistically significant (2.6% vs. 1.2%; RR 2.19). At one year, mortality rates remained numerically higher in the immediate group (4.7% vs. 3.5%), though this difference did not reach significance. Notably, there were no significant differences in MACCE, MI, or repeat revascularization between strategies — a finding that underscores the specific short-term mortality signal rather than a broad hazard.

Key outcomes: immediate vs. staged revascularization
ImmediateStaged
All-cause mortality at 30 days
2.0%1.2%
Cardiac mortality at 30 days *
2.6%1.2%
All-cause mortality at 1 year
4.7%3.5%
MACCE (short- and long-term)
No significant difference
* Statistically significant (RR 2.19; 95% CI 1.08–4.44). Source: Elbahloul et al., Circ Cardiovasc Interv 2026.

Experts note that interpretation of these trials has been complicated by the incorporation of myocardial infarction as a composite endpoint. Recurrent MI is notoriously difficult to adjudicate in the acute STEMI setting, and because biomarkers remain in flux, trials may be unintentionally biased toward immediate complete revascularization by failing to capture the true procedural MI burden in that group.

Cardiogenic Shock: The Highest-Risk Subgroup

The evidence is sharpest in patients presenting with STEMI complicated by cardiogenic shock. The CULPRIT-SHOCK trial demonstrated that immediate multivessel PCI in this population significantly increased 30-day mortality and the risk of severe renal failure requiring replacement therapy, compared with treating only the culprit artery. Though the current meta-analysis focuses on non-shock patients, experts note that the underlying physiological principles — a failing heart with no reserve to tolerate additional ischemic insult — apply broadly. The same concepts that drove the CULPRIT-SHOCK findings appear to manifest, with lesser intensity, even in hemodynamically stable STEMI patients.

What This Means in Practice

At many leading centers, the current default for STEMI patients with multivessel CAD is a staged approach. Immediate complete revascularization may still be considered in selected circumstances — such as when plaque rupture is present in two vessels simultaneously, or when a second vessel has such critical stenosis (near-total occlusion) that it is actively impairing flow. Outside of such scenarios, the prevailing advice is to stabilize the patient and return for a planned, functionally guided non-culprit PCI — either before hospital discharge or as an outpatient, based on the risk profile of the non-culprit disease.

The decision about when to perform the staged procedure may itself depend on the severity and characteristics of the non-culprit lesions. Higher-risk non-culprit disease may warrant revascularization prior to discharge; lower-risk lesions can often be safely deferred to an outpatient visit with functional assessment guiding the final decision.

Clinical Takeaways
  • Immediate complete revascularization in STEMI with multivessel CAD is associated with significantly higher cardiac mortality at 30 days vs. a staged strategy.
  • Culprit-only PCI at the index procedure remains the preferred approach for most patients.
  • Non-culprit lesions should be revisited in a staged procedure, guided by functional assessment (FFR/iFR) under stable conditions.
  • Trial results may underestimate procedural MI risk with immediate PCI due to inability to detect biomarker-defined infarction during the acute phase.
  • Cardiogenic shock patients face the greatest risk; culprit-only strategy is strongly supported by both CULPRIT-SHOCK and the broader meta-analytic evidence.
  • Immediate complete revascularization may still be justified in highly selected cases, such as multi-vessel plaque rupture or near-total non-culprit occlusion.

A More Measured Approach

The emerging consensus is one of strategic restraint. Open the culprit vessel. Stabilize the patient. Then, days to weeks later, revisit the angiogram with fresh eyes, functional data, and a physiology no longer distorted by the acute infarct. This staged philosophy allows clinicians to make calmer, more evidence-grounded decisions about which non-culprit lesions truly warrant intervention — and reduces the risk of compounding an already-stressed cardiovascular system with unnecessary procedural burden.

As the evidence base continues to mature, the message is becoming increasingly consistent: in STEMI with multivessel disease, timing is not a minor implementation detail — it is a clinically consequential decision in its own right.